Additionally, ADEs such as male endometriosis (n = 7; ROR 13,615.84, PRR 13,612.3, IC 10.73, EBGM 1,702.41), 5-alpha-reductase deficiency (n = 5; ROR 1,620.81, PRR 1,620.51, IC 9.79, EBGM 884.37), congenital bulbospinal muscular atrophy (n = 6; ROR 402.42, PRR 402.33, IC 8.38, EBGM 333.53), and double-hit lymphoma (n = 5; ROR 243.12, PRR 243.08, IC 7.76, EBGM 216.18) were recognized as potential new ADE signals that were not included in the drug’s labeling. Here, PSMA5 is linked to endometriosis.